Rheumatology Network's Top 5: July 30, 2021

July 30, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 30, 2021.

Roy Fleischmann, MD: Safety of JAK Inhibitors

Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.

Click the image to view the story.

Cardiovascular Autonomic Neuropathy Associated with Impaired Quality of Life in Patients with Lupus

Patients with systemic lupus erythematosus presented more cardiovascular autonomic neuropathy, along with impaired health-related quality of life and parasympathetic function, when compared with a control cohort.

Click the image to view the story.

Guselkumab Significantly Improves Fatigue in Patients With Psoriatic Arthritis

Guselkumab, an interleukin-23p19-subunit inhibitor, led to clinically significant and sustained improvements in fatigue through 1 year in patients with active psoriatic arthritis.

Click the image to view the story.

Lower Anti-Vaccine Antibody Levels Observed in Patients With Juvenile Idiopathic Arthritis

Many children with juvenile idiopathic arthritis stop vaccinating when diagnosis is established, despite them being at a greater risk of infections than healthy children due to their aberrant immunity and the use of immunosuppressive drugs.

Click the image to view the story.

Expert Perspectives: Improved Medication Adherence in Rheumatic Diseases

“Our study confirms challenges in selecting an appropriate outcome in interventional studies targeting medication adherence and the ways in which the lack of guidance in this area hinders research and limits our ability to compare interventions and draw conclusions about their effectiveness,” stated investigators.

Click the image to view the story.